Published on 02/12/2025

Peer Review Checklists for AI Documentation

Artificial Intelligence (AI) and Machine Learning (ML) technologies are becoming integral to the pharmaceutical industry, especially in Good Manufacturing Practice (GxP) settings. Ensuring compliance with regulatory requirements such as those outlined by the FDA, EMA, and MHRA does necessitate thorough documentation and validation protocols. This article provides a step-by-step guide to developing peer review checklists for AI documentation, focusing on various aspects of AI/ML model validation, including intended use, risk management, data readiness curation, bias and fairness testing, and model verification and validation.

Step 1: Understanding Intended Use & Data Readiness

The first crucial step in AI/ML model validation begins with a clear delineation of the intended use of the model and the necessary data readiness considerations. This is pivotal for ensuring that the model is developed with clearly defined goals in mind, allowing for streamlined validation processes.

• Identify Intended Use: Clarify the use cases for the AI model, including the specific functions it will perform in the pharmaceutical setting.
• Data Curation: Establish protocols for ensuring the data used for training and testing is appropriate, valid, and reflective of the intended application.
• Data Quality Assessment: Confirm that the data adheres to quality criteria, including completeness, accuracy, consistency, and timeliness.
• Compliance with Regulatory Guidelines: Ensure that the intended use and data readiness are aligned with relevant regulations like 21 CFR Part 11 and Annex 11.

Step 2: Risk Assessment for AI/ML Models

Following the identification of intended use, the next step involves risk assessment specific to AI/ML applications. Understanding and mitigating risks is paramount to uphold patient safety and product quality.

• Risk Identification: Compile a list of potential risks including algorithmic bias, data security concerns, model interpretability, and operational risks associated with deployment.
• Risk Analysis: Evaluate the potential impact and likelihood of each identified risk, facilitating prioritization of risk management strategies.
• Documentation: Document the risk assessment process to provide transparency and ensure comprehensive review; this comprises risk mitigation strategies implemented to address identified concerns.

Step 3: Bias and Fairness Testing

Bias and fairness are critical aspects of AI/ML systems due to their direct impact on outcomes in pharmaceutical processes. Implementing systematic testing for bias is essential.

• Selection of Metrics: Determine appropriate fairness metrics—such as demographic parity and equal opportunity—that are reflective of the model’s intended use.
• Conduct Bias Testing: Perform assessments to identify any bias present in the model outputs, utilizing varied datasets to examine model performance across different demographics.
• Bias Mitigation Strategies: If biases are detected, document the strategies employed to mitigate these biases, such as rebalancing datasets or adjusting model algorithms.
• Continuous Monitoring: Establish processes for ongoing monitoring of bias post-deployment to ensure continued fairness in output.

Step 4: Model Verification and Validation (V&V)

The verification and validation steps are critical milestones in the overall model development lifecycle. They ensure that the AI model is fit for use in its intended GxP context.

• Model Verification: Conduct verification processes to ensure that the model is developed correctly according to specifications. This may involve code reviews and test case validation.
• Model Validation: Carry out validation studies to confirm that the model performs as expected in real-world scenarios, assessing both accuracy and robustness.
• Documentation of V&V Processes: Maintain comprehensive records of verification and validation activities, including test results, methodologies used, and any deviations noted during the process.

Step 5: Explainability of AI Models

Explainability, or Explainable AI (XAI), focuses on making AI outcomes transparent and interpretable, which is especially vital in a regulatory setting where accountability matters.

• Define Explainability Needs: Identify the specific explainability requirements based on the intended use of the model and the stakeholders involved.
• Implement Explainability Tools: Utilize tools and frameworks for enhancing explainability, such as Shapley values or LIME (Local Interpretable Model-agnostic Explanations).
• Documentation: Thoroughly document the methods employed to explain AI model decisions, ensuring it adequately addresses the needs of regulators and end-users.

Step 6: Drift Monitoring and Re-validation

AI models are susceptible to changes over time—a phenomenon known as ‘drift.’ Regular drift monitoring and re-validation are essential to adapt them to evolving data landscapes.

• Establish Drift Indicators: Identify key performance indicators (KPIs) that signal potential drift in model performance, including shifts in accuracy over time.
• Implement Monitoring Protocols: Set up automated monitoring systems that alert stakeholders to performance discrepancies, enabling swift intervention when necessary.
• Documentation of Drift Events: Create records of drift events and the subsequent actions taken, including any re-validation efforts that are executed after modifications to the model.

Step 7: Documentation and Audit Trails

Robust documentation is pivotal in maintaining compliance and enabling effective audits. Develop a comprehensive documentation strategy that supports transparency and traceability in AI/ML processes.

• Develop a Documentation Framework: Create templates and guidelines for documenting all aspects of AI model development, validation, and deployment.
• Audit Trail Maintenance: Ensure that all changes to the model, including data adjustments, algorithm updates, and validation results, are meticulously logged in an audit trail.
• Compliance Checks: Periodically perform compliance checks on documentation to ensure adherence to regulatory requirements and to facilitate successful audits by regulatory agencies.

Step 8: AI Governance and Security

With responsible AI governance and security protocols, organizations can mitigate risks and maximize the benefits of AI technologies in the pharmaceutical sector.

• Establish Governance Structures: Form governance teams responsible for overseeing the development, deployment, and operational phases of AI models.
• Security Protocols: Implement cybersecurity measures to protect sensitive data used within AI/ML systems, including encryption and access control.
• Compliance with Ethical Standards: Ensure that AI governance frameworks encompass ethical considerations that align with regulatory expectations and industry standards.

Conclusion

The integration of AI/ML technologies into GxP environments necessitates strict adherence to documentation and validation protocols. By following the step-by-step guide outlined in this article, pharmaceutical professionals can develop comprehensive peer review checklists to ensure compliance with regulatory requirements and promote the responsible use of AI in drug development. Proper validation, monitoring, and documentation practices not only enhance the efficacy of AI models but also fortify trust in their deployment across the industry.